Evidence map›Paper›PMID 30527243›Full record

ArticleOral oncology2018

Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity.

Noriaki Tanaka, Abdullah A Osman, Yoko Takahashi, Antje Lindemann, Ameeta A Patel, Mei Zhao, Hideaki Takahashi, Jeffrey N Myers

Registry-linked trialAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Oral oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05375266 (Immune Biomarker Study for Head and Neck Cancer), which is not on this map. Cited by 87 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05375266 recruitingnot on this mapstarted 2022, after this paper: background citation

Immune Biomarker Study for Head and Neck Cancer

TypeobservationalSponsorUniversity of Erlangen-Nürnberg Medical SchoolRan2022 to 2027Enrolled1,100ConditionsHead and Neck Cancer, Oral Cavity Cancer, Oropharyngeal Cancer, Hypopharyngeal CancerArmsSampling
3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Observational
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. [Research and application progress of organoids in head and neck squamous cell carcinoma].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2026
    Review
  11. Review
  12. Article
  13. [Construction and application of oral squamous cell carcinoma organoid bank].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2025
    Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Noriaki TanakaDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Abdullah A OsmanDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Yoko TakahashiDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Antje LindemannDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ameeta A PatelDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Mei ZhaoDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Hideaki TakahashiDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jeffrey N MyersDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: jmyers@mdanderson.org.

Funding

Predicting and overcoming chemoradioresistance in p53-mutant head and neck cancerR01DE024601 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MYERS, JEFFREY NICHOLAS · 2014 to 2018
$2.6M
NIDCR NIH HHS R01 DE024601
6 · The paper itself

Abstract

objectivesCurrently there are no standard biomarkers of head and neck squamous cell carcinoma (HNSCC) response to therapy. This is, due to a lack of adequate predictive tumor models. To this end, we established cancer organoid lines from individual patient's tumors, and characterized their growth characteristics and response to different drug treatments with the objective of using these models for prediction of treatment response. MATERIALS AND

methodsForty-three patients' samples were processed to establish organoids. To analyze the character of these organoids, immunohistochemistry, Western blotting, drug sensitivity assays, clonogenic survival assays, and animal experiments were performed. The HPV status and TP53 mutational status were also confirmed in these lines.

resultsHNSCC organoids were successfully established with success rate of 30.2%. Corresponding two-dimensional cell lines were established from HNSCC organoids at higher success rate (53.8%). These organoids showed similar histological features and stem cell, epithelial and mesenchymal marker expression to the original tumors, thus recapitulating many of the characteristics of the original tumor cells. The cisplatin and docetaxel IC50 were determined for HNSCC organoids and the corresponding 2D cell lines using drug sensitivity and clonogenic survival assays. Responses to drug treatment in vivo were found to be similar to the IC

conclusionWe established novel in vitro HNSCC cancer organoid lines retaining many properties of the original tumors from they were derived. These organoids can predict in vivo drug sensitivity and may represent useful tools to develop precision treatments for HNSCC.

Indexed as

AnimalsAntineoplastic AgentsCisplatinDocetaxelDrug Screening Assays, AntitumorFemaleHead and Neck NeoplasmsHumansInhibitory Concentration 50MaleMiceOrganoidsPrimary Cell CultureSpheroids, CellularSquamous Cell Carcinoma of Head and NeckTumor Cells, CulturedAntineoplastic AgentsCisplatinDocetaxel3D cultureCancer organoidCancer tissue-originated spheroid (CTOS)CisplatinDocetaxelDrug sensitivity assayHead and neck cancerHPV-positive

Identifiers

PMID30527243
PMCPMC6294331

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.